+91 22 24172311
Sections
Search
Subscribe
Equity
Venture Capital
Private Equity
M&A
Mergers & Acquisitions | 27 November 2012

Otsuka Pharma May Acquire Injectibles Biz Of Claris Lifesciences

by Charmi Gutka
 
@charmi

@Claris_Lifesciences is planning to sell its injectibles business and it is in preliminary talks with Japanese Pharma firm - Otsuka Pharma for the same.

IDFC and Barclays are the bankers to the deal, ET stated.

This news comes after the announcement by Strides Arcolabs to put up its injectable-drugs unit, @Agila_Specialties Private Limited for sale.

Ahmedabad based, Claris Lifesciences offers injectibles in various therapeutic segments including anesthesia, critical care, anti-infectives, renal care, infusion therapy, parenteral nutrition and oncology.

It has presence in 91 countries across Latin America, Europe, Gulf, Africa, CIS, Central Asia and Asia- Pacific. Last month, Mitsui of Japan, through its healthcare arm, was plnning to invest R250 Cr in Claris.

MakeMyTrip Makes Second Acquisition This Month: Acquires Thai Group ITC

U.S listed travel portal MakeMyTrip has acquired majority stake in ITC Group, enhancing its South East Asian portfolio of offerings.

Read More...

Nexus Venture Buys Stake In Startup Function Space

Pune based education startup Function Space has raised an undisclosed amount of funding in seed round from Nexus India Capital to strengthen its existing content and also increase its current userbase.

Read More...
TL Home Search New Keet
CONTACT US
Info@DealCurry.com
+91 22 24172311
A 311, 3rd Floor, AntopHill Warehousing Company,
Near Dosti Acres
Wadala(E),
Mumbai 400037
   
 
CLIENTS
USEFUL LINKS
SOLUTIONS
Copyright © EagleEye Research & Media Pvt. Ltd. 2009 All Rights Reserved - Interactive multimedia analysis platform for financial markets.
Site map |Terms of Use |Privacy Policy
DealCurry tracks financial and corporate markets for events, interprets and integrates the information in our platform, providing premium data, news and analytics. DealCurry provides comprehensive coverage of the capital markets through an intuitive, user-friendly interface.